Preliminary results of MSF malaria prevention program suggest malaria drugs prevent disease in healthy children

NewsGuard 100/100 Score

A large-scale malaria prevention program through which medical aid group Medecins Sans Frontieres (MSF) gave intermittent doses of anti-malaria drugs to 175,000 children in Mali and Chad suggests that "widely distributing anti-malaria drugs to healthy children in African countries can significantly reduce the number of new cases of the disease," VOA News reports. "The [program] was launched in July and will continue through next month, a period of high transmission for malaria," the news service notes (9/24). "Preliminary results from the program, known as seasonal malaria chemoprevention (SMC), show that the number of cases of simple malaria dropped by 65 percent in the intervention area in Mali, and by up to 86 percent in Chad," according to an MSF press release, which adds, "A significant decrease in cases of severe malaria has also been recorded."

"The World Health Organization (WHO) recommended SMC in March 2012, based upon research carried out in African countries that experience high levels of seasonal malaria," the press release states. "SMC consists of the intermittent provision of a full course anti-malaria treatment during peak malaria season," it notes, adding, "The projects mark the first time that MSF has carried out a large-scale SMC program" (9/24). In an accompanying interview on the organization's website, MSF Tropical Medicine Adviser Estrella Lasry "reflects on the different aspects and future prospects of this strategy" (9/24).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vosoritide's first phase 2 study shows increased growth in children with hypochondroplasia